Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Craig Johnson

Surgery Tulsa, OK Medical Doctor

NPI 1780645531 CMS profile 308056

2448 E 81St St, Suite 1100, Tulsa, OK 74137

Open in the dashboard

General payments

$573,399

703 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Craig Johnson of Tulsa, OK is reported in the CMS Open Payments database as having received $573,399 across 703 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $30 1
2023 General $16 1
2022 General $65 2
2021 General $276 12
2020 General $114,083 127
2019 General $458,928 560

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Craig Johnson
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Craig Johnson were reported at $0. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Craig Johnson Surgery median Middle half National median
2019 $458,928 $253 $82–$1,521 $163
2020 $114,083 $131 $40–$706 $114
2021 $276 $168 $50–$904 $132
2022 $65 $224 $76–$1,218 $149
2023 $16 $253 $82–$1,255 $160
2024 $30 $279 $90–$1,381 $164
2025 $0 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Intuitive Surgical, Inc. $572,318 661 payments
  2. CONMED Corporation $224 4 payments
  3. Allergan Inc. $162 6 payments
  4. Davol Inc. $141 3 payments
  5. Ferring Pharmaceuticals Inc. $134 9 payments
  6. Biom'Up France SAS $48 1 payment
  7. Merck Sharp & Dohme Corporation $46 3 payments
  8. Baudax Bio Inc. $37 2 payments
  9. KCI USA, Inc $35 2 payments
  10. Medtronic, Inc. $30 1 payment
  11. Other $225 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Education $345,176 146 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $139,450 52 payments
  3. Travel and Lodging $62,181 240 payments
  4. Food and Beverage $26,591 265 payments
Products named General payments · program years 2019–2024
  1. Da Vinci Surgical System $572,318 661 payments
  2. AirSeal General Surgery $176 3 payments
  3. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $137 5 payments
  4. CLENPIQ $134 9 payments
  5. PHASIX $124 2 payments
  6. AIRSEAL General Surgery $48 1 payment
  7. HemoBlast Bellows $48 1 payment
  8. BRIDION $46 3 payments
  9. GATTEX $41 2 payments
  10. ANJESO $37 2 payments
  11. Other $412 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

133

Median for Colorectal Surgery (Proctology): 106

Drug cost

$7,534

Median for Colorectal Surgery (Proctology): $1,614

Branded share of claims

47.4%

Median for Colorectal Surgery (Proctology): 35.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 37 $6,366
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 11 $631
Metronidazole Generic 24 $148
Baclofen Generic 11 $140
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $97
Neomycin Sulfate Generic 18 $96
Chlorhexidine Gluconate Generic 17 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,507 Part D prescribers listed as Colorectal Surgery (Proctology); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$26,658

Medicare's payments for the services billed

Medicare patients

106

Average age 74

Services billed

170

62 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 38%
Depression 29%
Cancer 28%
Chronic kidney disease 25%
Atrial fibrillation 22%
Diabetes 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

703 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record